![Pierre Léonard](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Pierre Léonard
Corporate Officer/Principal at Enobia Pharma, Inc.
Pierre Léonard active positions
Companies | Position | Start | End |
---|---|---|---|
Enobia Pharma, Inc.
![]() Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Corporate Officer/Principal | 01/07/2009 | - |
Career history of Pierre Léonard
Training of Pierre Léonard
University of Cincinnati (Ohio) | Doctorate Degree |
Statistics
International
Canada | 2 |
United States | 2 |
Operational
Corporate Officer/Principal | 1 |
Doctorate Degree | 1 |
Sectoral
Health Technology | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Enobia Pharma, Inc.
![]() Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
- Stock Market
- Insiders
- Pierre Léonard
- Experience